Vanguard lists 6.10M shares (5.54%) of Quest Diagnostics
Rhea-AI Filing Summary
Vanguard Portfolio Management reports beneficial ownership of 6,096,629 shares of Quest Diagnostics Inc. Common Stock (CUSIP 74834L100), representing 5.54% of the class as reported in a Schedule 13G. The filing states sole voting power of 15,229 shares and sole dispositive power over the full 6,096,629 shares. The disclosure is signed by Ashley Grim on 04/29/2026 and describes holdings managed across Vanguard affiliates and funds.
Positive
- None.
Negative
- None.
Insights
Large passive stake disclosed: Vanguard holds 6.10M shares (5.54%) of Quest Diagnostics.
The Schedule 13G shows Vanguard Portfolio Management beneficially owns 6,096,629 shares with sole dispositive power, indicating portfolio management control across Vanguard funds and managed accounts. The filing follows the Investment Company Act of 1940 disclosure practice.
This is a routine institutional ownership disclosure; the filing does not state any planned transactions or changes to holdings. Subsequent filings would be needed to detect active buying/selling or changes to voting arrangements.
Key Figures
Key Terms
beneficially owned regulatory
sole dispositive power regulatory
Schedule 13G regulatory
Investment Company Act of 1940 regulatory
FAQ
What stake does Vanguard hold in Quest Diagnostics (DGX)?
When was the Schedule 13G for DGX signed?
What does this Schedule 13G filing indicate about Vanguard's intentions?
Which Vanguard entities are referenced in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.